GYNECOLOGIC COMPLICATIONS ASSOCIATED WITH LONG-TERM ADJUVANT TAMOXIFEN THERAPY FOR BREAST-CANCER

被引:66
作者
WOLF, DM
JORDAN, VC
机构
[1] Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison
关键词
D O I
10.1016/0090-8258(92)90273-L
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The antiestrogen tamoxifen was originally introduced as a therapy for advanced breast cancer. Today, tamoxifen is used to treat selected patients with all stages of breast cancer, and trials are underway to evaluate its effectiveness as a potential breast cancer preventive. When tamoxifen is used as an adjuvant or preventive, extended patient survival times can be expected, and concerns about iatrogenic complications arising from long-term treatment become important. This review discusses currently available laboratory and clinical data regarding the toxicology of tamoxifen and focuses in particular on the gynecologic complications potentially associated with long-term tamoxifen administration. © 1992.
引用
收藏
页码:118 / 128
页数:11
相关论文
共 139 条
[1]   RANDOMIZED TRIAL OF TAMOXIFEN VERSUS AMINOGLUTETHIMIDE AND VERSUS COMBINED TAMOXIFEN AND AMINOGLUTETHIMIDE IN ADVANCED POSTMENOPAUSAL BREAST-CANCER [J].
ALONSOMUNOZ, MC ;
OJEDAGONZALEZ, MB ;
BELTRANFABREGAT, M ;
DORCARIBUGENT, J ;
LOPEZLOPEZ, L ;
BORRASBALADA, J ;
CARDENALALEMANV, F ;
GOMEZBATISTE, X ;
FABREGATMAYOL, J ;
VILADIUQUEMADA, P .
ONCOLOGY, 1988, 45 (05) :350-353
[2]   INCIDENCE OF NEW PRIMARY CANCERS AFTER ADJUVANT TAMOXIFEN THERAPY AND RADIOTHERAPY FOR EARLY BREAST-CANCER [J].
ANDERSSON, M ;
STORM, HH ;
MOURIDSEN, HT .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (14) :1013-1017
[3]  
[Anonymous], 1988, NEW ENGL J MED, V319, P1681
[4]   ENDOMETRIAL CANCER AND ESTROGEN USE - REPORT OF A LARGE CASE-CONTROL STUDY [J].
ANTUNES, CMF ;
STOLLEY, PD ;
ROSENSHEIN, NB ;
DAVIES, JL ;
TONASCIA, JA ;
BROWN, C ;
BURNETT, L ;
RUTLEDGE, A ;
POKEMPNER, M ;
GARCIA, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (01) :9-13
[5]  
BAUM M, 1988, BRIT J CANCER, V57, P608
[6]  
BAUM M, 1983, LANCET, V1, P257
[7]  
BAUM M, 1985, LANCET, V1, P836
[8]  
Beatson G., 1896, LANCET, V148, P162, DOI DOI 10.1016/S0140-6736(01)72384-7
[9]  
Beatson G.T., 1896, LANCET, V15, P153, DOI DOI 10.1016/S0140-6736(01)72307-0
[10]   TAMOXIFEN AS A POSSIBLE CHEMOTHERAPEUTIC AGENT IN ENDOMETRIAL ADENOCARCINOMA [J].
BONTE, J ;
IDE, P ;
BILLIET, G ;
WYNANTS, P .
GYNECOLOGIC ONCOLOGY, 1981, 11 (02) :140-161